To contrast that, a 2025 study suggests injectable semaglutide provides better blood sugar control
Poorly designed devices may experience stalls, delayed injection start or premature removal, all of which can negatively impact patient experience, adherence and treatment outcomes
5 Persistence and discontinuation Persistence with GLP-1 therapy has been a major concern
Substantial Weight Loss Over 68 Weeks Participants who received the highest dose (12 mg) experienced an average 28.7 % reduction in body weight, equivalent to roughly 71.2 lbs from their starting weights over 68 weeks, far greater than the placebo group, which saw about a 2.1 % reduction
In this regard, it is noteworthy that a selective glucagon receptor antagonist increased hepatic fat in patients with T2D 23
As part of their agreements with CMS, the manufacturers must demonstrate how these lifestyle support programs will meet the program requirements, including encouraging healthy eating and increasing physical activity, supporting medication adherence, ensuring engagement with the program on a regular basis, and ensuring availability of this program to all patients receiving these medications, either online or offline for those who have limited digital access